Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Anthracenedione
Mitoxantrone
Novantrone · MITO
An anthracenedione with minimal direct renal toxicity — its kidney risk is tumor lysis, and blue-green urine is benign.
MildAnthracenedione (topoisomerase II inhibitor) · approved 1987
Acute myeloid leukemia (in combination)Hormone-refractory/advanced prostate cancer (with corticosteroids)Secondary-progressive or worsening relapsing-remitting multiple sclerosis
Signature kidney injury
Prerenal / Hemodynamic AKI
Direct nephrotoxicity is low and not quantified; the principal renal risk is tumor lysis syndrome when used in bulky/rapidly proliferating hematologic malignancies. Benign blue-green discoloration of urine/sclera is expected (the anthracenedione chromophore), not injury.
Source: Tannock et al., NEJM 2004
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
Incidence not quantified
SeverityMild
ReversibilityReversible
Evidence0 refs
Nephron map
Vasculature / EndotheliumGlomerular & peritubular capillaries
Distal Tubule / Collecting Duct
Tubular Lumen
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Mechanism of kidney injury
Low direct nephrotoxicity. The dominant renal mechanism is tumor lysis — massive cell lysis releases purines (uric acid crystal nephropathy in the distal nephron/collecting duct) and phosphate (calcium-phosphate crystal deposition), causing obstructive intratubular crystallopathy and AKI, with hemodynamic/prerenal contributions.
Clinical presentation
When tumor lysis occurs: a rising uric acid, potassium, phosphate and LDH with a falling calcium and oliguric AKI within 12-72 h of dosing. Benign blue-green urine/scleral discoloration is expected and is not a sign of injury.
Onset
Tumor lysis hours to days post-infusion.
Reversibility
Reversible
Anticancer mechanism
Anthracenedione that intercalates DNA and inhibits topoisomerase II, causing DNA strand breaks and impaired replication/repair; it generates fewer free radicals per dose than classic anthracyclines, though cumulative cardiotoxicity remains.
Management
Aggressive IV hydration, rasburicase for hyperuricemia, electrolyte correction, and renal replacement therapy for refractory metabolic derangement. The blue-green discoloration requires only reassurance.
Risk factors
- High tumor burden/high WBC and high LDH
- Pre-existing renal impairment and volume depletion
- Proliferative AML subtypes
Prevention
- Hydration; allopurinol for intermediate-risk and rasburicase for high-risk tumor lysis
- Avoid urinary alkalinization
- Track cumulative dose (cardiotoxicity is dose-limiting, ~140 mg/m2 lifetime, lower after prior anthracycline)
Note · Established (1987) agent; renal events are tumor-lysis-driven and not population-quantified.
Clinical depth
Renal dose adjustment
No well-defined renal CrCl thresholds (minimal renal elimination — predominantly hepatobiliary clearance); reduce/monitor in hepatic impairment. Cumulative dose is limited by cardiotoxicity rather than renal function.
Dialyzability & ESKD dosing
Not appreciably dialyzable (large volume of distribution and high tissue/protein binding); dialysis is used for tumor-lysis metabolic management.
Differential diagnosis
Tumor lysis versus benign anthracenedione pigment (harmless) versus contrast/sepsis AKI versus concomitant nephrotoxins.
Monitoring
- Tumor-lysis labs (uric acid, potassium, phosphate, calcium, LDH), CBC
- Cumulative anthracenedione dose tracking
- LVEF/cardiac monitoring
Key trials & series
- TAX 327 (Tannock, NEJM 2004) — defining mitoxantrone comparator trial in prostate cancer
- AML15 (Burnett, J Clin Oncol 2013) — mitoxantrone in AML consolidation
Clinical pearls
- Direct mitoxantrone nephrotoxicity is minimal — think tumor lysis, not tubular drug toxicity.
- Blue-green urine and scleral discoloration are benign.
- Renal clearance is minor (hepatobiliary), so renal dose-cut thresholds are not well established.
- Cardiotoxicity, not nephrotoxicity, is the dose-limiting organ toxicity.
Where it strikes
Nephron segments
Tubular Lumen
The urine flow path
Distal Tubule / Collecting Duct
Fine-tuning of Na, K, Mg, acid & water
Injury signatures
Crystal / Obstructive NephropathyElectrolyte WastingPrerenal / Hemodynamic AKI
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.Tannock IF et al. · N Engl J Med 2004 · PMID 15470213TAX 327 phase 3 — defining mitoxantrone comparator trial in prostate cancer.PMIDOptimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.Burnett AK et al. · J Clin Oncol 2013 · PMID 23940227Large randomized AML trial using mitoxantrone in consolidation.PMIDTumor lysis syndrome following single-dose mitoxantrone.Benekli M et al. · Chemotherapy 1995 · PMID 8529438Documents mitoxantrone-induced tumor lysis syndrome (single agent).PMIDTumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.Howard SC et al. · Ann Hematol 2016 · PMID 26758269Systematic tumor-lysis review including mitoxantrone-containing regimens.PMIDGuidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.Coiffier B et al. · J Clin Oncol 2008 · PMID 18509186Standard tumor-lysis risk-stratification and rasburicase/allopurinol/hydration management.PMIDThe tumor lysis syndrome.Howard SC et al. · N Engl J Med 2011 · PMID 21561350Authoritative tumor-lysis pathophysiology (uric acid/phosphate crystal nephropathy) and management review.
Related agents
Other agents sharing the same signature kidney injury.